Rallybio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.65	0.86	0.64	-	-	-
Revenue Growth	-15.11%	34.91%	-	-	-	-
Cost of Revenue	17.19	18.4	39.51	53.54	-	-
Gross Profit	-16.54	-17.54	-38.87	-53.54	-	-
Selling, General & Admin	16.24	13.83	18.33	25.39	27.2	18.74
Research & Development	-7.36	-	-	-	40.69	26.91
Operating Expenses	8.88	13.83	18.33	25.39	67.88	45.65
Operating Income	-25.42	-31.36	-57.2	-78.93	-67.88	-45.65
Interest Expense	-	-	-	-	-	-0.01
Interest & Investment Income	1.44	2.19	4.22	6.15	1.96	0.05
Earnings From Equity Investments	-	-0.87	-2.24	-2.04	-1.08	-1.51
Other Non Operating Income (Expenses)	50.81	0.42	0.74	0.26	0.34	0.1
EBT Excluding Unusual Items	26.83	-29.63	-54.48	-74.56	-66.65	-47.01
Merger & Restructuring Charges	-2.3	-1.7	-3.3	-	-	-
Gain (Loss) on Sale of Investments	22.35	22.35	-	-	-	-
Pretax Income	46.88	-8.98	-57.78	-74.56	-66.65	-47.01
Income Tax Expense	1.32	-	-	-	-	-
Net Income	45.55	-8.98	-57.78	-74.56	-66.65	-47.01
Net Income to Common	45.55	-8.98	-57.78	-74.56	-66.65	-47.01
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	6	6	5	5	4	3
Shares Outstanding (Diluted)	6	6	5	5	4	3
Shares Change	2.02%	3.42%	7.66%	27.11%	24.70%	46.76%
EPS (Basic)	8.03	-1.59	-10.61	-14.75	-16.76	-14.74
EPS (Diluted)	7.99	-1.59	-10.61	-14.75	-16.76	-14.74
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	26.71	-29.81	-49.28	-60.28	-57.34	-45.87
Free Cash Flow Per Share	4.68	-5.30	-9.05	-11.92	-14.41	-14.38
Operating Margin	-3935.45%	-3655.48%	-8993.08%	-	-	-
Profit Margin	7051.24%	-1046.39%	-9084.12%	-	-	-
Free Cash Flow Margin	4134.99%	-3474.71%	-7748.74%	-	-	-
EBITDA	-25.38	-31.27	-57.07	-78.78	-67.72	-45.54
D&A For EBITDA	0.04	0.09	0.13	0.15	0.17	0.11
EBIT	-25.42	-31.36	-57.2	-78.93	-67.88	-45.65
Revenue as Reported	0.65	0.86	0.64	-	-	-

SEC Filings: 10-K · 10-Q